



27 January 2021  
EMA/56099/2021  
Human Medicines Division

## Overview of (invented) names reviewed in November 2020 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 25-29 January 2021

|   | NRG meeting<br>25-26 Feb 2020 |          | NRG meeting<br>23 Apr 2020 |          | NRG meeting<br>02-03 June<br>2020 |          | NRG meeting<br>30 Jun-01 Jul<br>2020 |          | NRG meeting<br>15-16 Sep 2020 |          | NRG meeting<br>24-25 Nov 2020 |          | 2020 total |            |
|---|-------------------------------|----------|----------------------------|----------|-----------------------------------|----------|--------------------------------------|----------|-------------------------------|----------|-------------------------------|----------|------------|------------|
|   | Accepted                      | Rejected | Accepted                   | Rejected | Accepted                          | Rejected | Accepted                             | Rejected | Accepted                      | Rejected | Accepted                      | Rejected | Accepted   | Rejected   |
| Proposed (invented) names*                        | 44                            | 69       | 19                         | 33       | 42                                | 31       | 49                                   | 28       | 57                            | 38       | 59                            | 50       | <b>270</b> | <b>249</b> |
| Justification for retention of (invented) name ** | 6                             | 11       | 0                          | 0        | 5                                 | 9        | 0                                    | 0        | 5                             | 3        | 0                             | 5        | <b>16</b>  | <b>28</b>  |

\*Includes invented names, INN+MAH/TM and re-use applications.

\*\*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



|   | NRG meeting<br>26-27 Feb 2020 |          | NRG meeting<br>23 Apr 2020 |          | NRG meeting<br>02-03 June<br>2020 |          | NRG meeting<br>30 Jun-01 Jul<br>2020 |          | NRG meeting<br>18 Sep 2020 |          | NRG meeting<br>22 Nov 2020 |          | 2020 total |            |
|---|-------------------------------|----------|----------------------------|----------|-----------------------------------|----------|--------------------------------------|----------|----------------------------|----------|----------------------------|----------|------------|------------|
|   | Accepted                      | Rejected | Accepted                   | Rejected | Accepted                          | Rejected | Accepted                             | Rejected | Accepted                   | Rejected | Accepted                   | Rejected | Accepted   | Rejected   |
| Total number of objections raised   | 141                           | 213      | 96                         | 120      | 58                                | 109      | 53                                   | 126      | 85                         | 89       | 122                        | 175      | <b>555</b> | <b>832</b> |
| <b>Criterion - Safety concerns</b>  |                               |          |                            |          |                                   |          |                                      |          |                            |          |                            |          |            |            |
| Similarity with other (invented) name   | 115                           | 154      | 81                         | 85       | 49                                | 88       | 49                                   | 89       | 71                         | 75       | 101                        | 115      | <b>466</b> | <b>606</b> |
| Conveys misleading therapeutic/pharmaceutical connotations  | 2                             | 6        | 1                          | 2        | 1                                 | 0        | 1                                    | 2        | 0                          | 0        | 3                          | 0        | <b>8</b>   | <b>10</b>  |
| Misleading with respect to composition  | 0                             | 0        | 0                          | 0        | 0                                 | 0        | 0                                    | 0        | 0                          | 0        | 0                          | 1        | <b>0</b>   | <b>1</b>   |
| <b>Criterion - INN concerns</b>   |                               |          |                            |          |                                   |          |                                      |          |                            |          |                            |          |            |            |
| Similarity with INN   | 7                             | 1        | 8                          | 4        | 3                                 | 0        | 0                                    | 0        | 9                          | 0        | 6                          | 8        | <b>33</b>  | <b>13</b>  |
| Inclusion of INN stem   | 2                             | 0        | 0                          | 0        | 0                                 | 0        | 0                                    | 1        | 0                          | 0        | 1                          | 0        | <b>3</b>   | <b>1</b>   |
| <b>Criterion - Other public health concerns</b>   |                               |          |                            |          |                                   |          |                                      |          |                            |          |                            |          |            |            |
| Unacceptable qualifiers   | 0                             | 0        | 0                          | 0        | 0                                 | 0        | 0                                    | 0        | 0                          | 2        | 3                          | 2        | <b>3</b>   | <b>4</b>   |
| Conveys a promotional message   | 4                             | 5        | 2                          | 4        | 2                                 | 2        | 2                                    | 4        | 1                          | 2        | 3                          | 8        | <b>14</b>  | <b>25</b>  |
| Appears offensive or has an inappropriate connotation   | 0                             | 1        | 1                          | 0        | 0                                 | 0        | 0                                    | 0        | 1                          | 0        | 0                          | 1        | <b>2</b>   | <b>2</b>   |
| Similarity between name of individual active substance and fixed combinations and/or between fixed combinations | 0                             | 0        | 0                          | 0        | 0                                 | 0        | 0                                    | 0        | 0                          | 0        | 0                          | 0        | <b>0</b>   | <b>0</b>   |
| Similarity between name of prodrug and related active substance   | 0                             | 0        | 0                          | 0        | 0                                 | 0        | 0                                    | 0        | 0                          | 0        | 0                          | 0        | <b>0</b>   | <b>0</b>   |
| Others  | 11                            | 46       | 3                          | 25       | 3                                 | 19       | 1                                    | 30       | 3                          | 10       | 8                          | 48       | <b>29</b>  | <b>178</b> |

See *Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#)* for detailed explanations of criteria used.